Avexitide

Generic Name: Avexitide

Drug Type: Small Molecule

Chemical Formula: C_₁₄₉H_₂₃₄N_₄₀O_₄₇S

CAS Number: 133514-43-9

Unique Ingredient Identifier: 5313W10MYT

Background: Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).

Clinical Trials

Glucagon Like Peptide-1 in Remote Ischemic Conditioning

Not Applicable

Completed

Conditions: Healthy Volunteers

Interventions: Other: Remote conditioning
Drug: Exendin 9-39

First Posted Date: 2016-04-21

Last Posted Date: 2018-03-07

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 12

Registration Number: NCT02746757

Locations: 🇸🇪
Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

Phase 1

Terminated

Conditions: Hypoglycemia

Interventions: Other: Placebo
Drug: Exendin (9-39)

First Posted Date: 2015-09-15

Last Posted Date: 2024-12-04

Lead Sponsor: Tracey McLaughlin

Target Recruit Count: 10

Registration Number: NCT02550145

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery

Not Applicable

Completed

Conditions: Severe Obesity

Interventions: Other: Placebo
Drug: sitagliptin
Drug: exendin 9-39

First Posted Date: 2015-01-13

Last Posted Date: 2016-06-21

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 12

Registration Number: NCT02336659

Locations: 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark

Determinants of Diabetes Remission After Gastric Bypass Surgery

Early Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Exendin9

First Posted Date: 2014-11-10

Last Posted Date: 2020-04-24

Lead Sponsor: Blandine Laferrere

Target Recruit Count: 25

Registration Number: NCT02287285

Locations: 🇺🇸
New York Obesity Research Center, Columbia University, New York, New York, United States

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

Phase 2

Completed

Conditions: Dyspepsia
Diabetes Mellitus With Gastrointestinal Symptoms

Interventions: Drug: Exendin 9-39
Drug: Placebo
Drug: Microlipid

First Posted Date: 2014-06-23

Last Posted Date: 2019-04-23

Lead Sponsor: Mayo Clinic

Target Recruit Count: 104

Registration Number: NCT02170870

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

Phase 1

Completed

Conditions: Appetite and General Nutritional Disorders

Interventions: Dietary Supplement: Saline
Drug: Exendin 9-39
Drug: Exendin(9-39) plus ID nutrient

First Posted Date: 2013-07-16

Last Posted Date: 2013-07-16

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 12

Registration Number: NCT01900340

Locations: 🇨🇭
University Hospital Basel, Phase 1 Research Unit, Basel, Switzerland

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Phase 1

Completed

Conditions: Monogenic Diabetes

Interventions: Drug: GLP-1
Drug: Exendin 9-39

First Posted Date: 2013-02-20

Last Posted Date: 2017-04-10

Lead Sponsor: University of Chicago

Target Recruit Count: 10

Registration Number: NCT01795144

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Effect of GLP-1 on Postprandial Lipid Metabolism

Not Applicable

Conditions: Heart Disease

Interventions: Drug: GLP-1
Other: saline
Drug: Exendin-9

First Posted Date: 2013-01-04

Last Posted Date: 2013-01-04

Lead Sponsor: David Dalessio

Target Recruit Count: 42

Registration Number: NCT01760772

Locations: 🇺🇸
Veteran's Affairs Clinical Research Unit, Cincinnati, Ohio, United States

Ghrelin Effect on Beta Cell Function in Health and Disease

Not Applicable

Conditions: Diabetes

Interventions: Drug: saline
Drug: Exendin (9-39)
Drug: acyl ghrelin

First Posted Date: 2012-11-20

Last Posted Date: 2013-04-04

Lead Sponsor: David Dalessio

Target Recruit Count: 30

Registration Number: NCT01729299

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States

Effect of DPP4 Inhibition on Growth Hormone Secretion

Phase 4

Completed

Conditions: Obesity

Interventions: Drug: Sitagliptin
Drug: Placebo
Drug: Pegvisomant
Drug: Exendin 9-39
Drug: L-NMMA

First Posted Date: 2012-10-05

Last Posted Date: 2018-05-29

Lead Sponsor: Vanderbilt University

Target Recruit Count: 44

Registration Number: NCT01701973

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy